NuCana (NASDAQ:NCNA) Stock Price Up 2.9% – Time to Buy?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s stock price shot up 2.9% on Thursday . The company traded as high as $1.44 and last traded at $1.43. 49,000 shares changed hands during trading, a decline of 50% from the average session volume of 97,747 shares. The stock had previously closed at $1.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

NuCana Trading Up 2.9%

The firm has a market cap of $5.95 million, a P/E ratio of -0.38 and a beta of 2.23. The company’s 50 day simple moving average is $1.41 and its 200-day simple moving average is $1.77.

NuCana (NASDAQ:NCNA) last issued its earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.65) by $1.66.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.